Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya26774Research ArticleNeksavar® (sorafenib)v lechenii rasprostranennogo pochechno-kletochnogo rakaPodregul'skiyK E-15062009112535409042020Copyright © 2009, Consilium Medicum2009рак почкипочечно-клеточный ракметастазыхимиотерапияингибитор тироксинкиназысорафенибНексавар[Аксель Е.М., Давыдов М.И. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Вест. РОНЦ им. Н.Н.Блохина РАМН. 2008; 2 (19).][Матвеев Б.П., Матвеев В.Б., Волкова М.И. Онкоурология. 2008; 4.][Petrilak D et al. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin Am 1993; 29A: 997.][Savage P.D. Renal cell cancer. Lippincott Co; 1995.][Strumberg D et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965–72.][Clark J.W. et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43- 9006 in patients with advanced refractory solid tumors. Clin Cancer Res 2005; 11: 5472–80.][Awada A et al. Phase I clinical and pharmacokinetic of BAY 43-9006 administered for 21 days on 7 days off in patients with advanced refractory solid tumors. Br J Cancer 2005; 92: 1855–61.][Amato R et al. Phase II trail of intra-patient dose - escalated sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25: abstr 5026.][Szczylik C et al. Randomized phase II trail of first - line treatment with sorafenib vs interferon in patients with advanced renal cell carcinoma. J ClinOncol 2007; 25: abstr 5025.][Ryan C.W., Goldman B.N. et al. Sorafenib plus interferon-?2b as first - line therapy for advanced renal cell carcinoma: SWOG 0412. J Clin Oncol 2006; 24: abstr 4525.][Gollob J et al. Комбинация сорафениба и интерферона альфа-2b в 1–2 линиях терапии метастатического почечноклеточного рака: исследование II фазы. J Clin Oncol (русское издание). 2007; 1 (4).][Ratain M.J., Elsen T et al. Phase II placebo.-.controlled randomized discontination trail of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–12.][Escudier B, Szczylik C et al. Randomized phase III trail of the multikinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Eur J Canc 2005; 3: 226.][Escudier B, Eisen T et al. Sorafenib in Advanced Clear - Cell Renal - Cell Carcinoma. N Engl J Med 2007; 357: 203.][Bukowski R et al. Final results of the randomized phase III trail of sorafenib in advanced renal cell carcinoma. Survival and biomarker analisis. J Clin Oncol 2007; 25: abstr 5023.][Knox J.J., Figlin R et al. Inv Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded accsess trail in North America: Safety and efficacy. J Clin Oncol 2007; 25: abstr 5011.][NCCN Clinical Practice Guidelines in OncologyTM. Kidney Cancer]